Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 7;16(1):116.
doi: 10.1186/s12985-019-1220-y.

Serum and tissue miRNAs: potential biomarkers for the diagnosis of cervical cancer

Mahdieh Farzanehpour  1 , Sayed-Hamidreza Mozhgani  2   3 , Somayeh Jalilvand  1 , Ebrahim Faghihloo  4 , Setareh Akhavan  5 , Vahid Salimi  1 , Talat Mokhtari Azad  6
Affiliations

Serum and tissue miRNAs: potential biomarkers for the diagnosis of cervical cancer

Mahdieh Farzanehpour et al. Virol J. .

Abstract

Background: Finding new biomarkers for the early detection of cervical cancer is an essential requirement in this field. In this study, we aimed to evaluate the expression level of potential biomarkers in progression of cervical cancer in patients with cervical cancer compared to normal subjects.

Methods: The expression levels of tissue and serum miRNAs, including miR-9, miR-192 and miR-205, were investigated in 36 normal, 18 precancer, and 18 cervical cancer samples using real-time polymerase chain reaction.

Results: The results showed the higher significant expressions of miR-9, miR-192 and miR-205 in the tissue of cancer samples than those in the normal samples. Moreover, the miR-192 and miR-205 expression were significantly increased in the cancer group in comparison with the precancer group. Examination of serum samples revealed the increase in the expression level in the cancer groups than in the normal samples, for miR-9, miR-192 and miR-205 and the expressions of miR-9, miR-192 and miR-205 were significantly up-regulated in the precancer group in comparison with the normal group. Also the expression of miR-205 was remarkably increased in the cancer group in comparison with the precancer group. The receiver operating characteristic (ROC) analyses showed the highest area under the curve value for miR-192.

Conclusions: Given the increased expression level of miR-192 in cancer and in precancerous tissue and serum compared with the normal tissue and serum validated by analysing the ROC curve, miR-192 can be used as potential biomarker for the early detection of cervical cancer.

Keywords: Cervical cancer; Human papillomavirus; miRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no competing interest.

Figures

Fig. 1
Fig. 1
Relative expression levels of miR-9, miR-192 and miR-205 among the cervical cancer, precancer and normal groups in the (a) tissue and (b) serum samples. Each sample was analysed in triplicate and normalised to U6
Fig. 2
Fig. 2
ROC curve analysis using miR-9, miR-192 and miR-205 to distinguish the different groups in the tissue samples. The area under the curve (AUC) values in the cervical cancer and normal groups (a), the AUC values in the precancer and normal groups (b) and The AUC values in the cervical cancer and precancer groups (c). The red, blue and green lines represent miR-192, miR-9 and miR-205, respectively
Fig. 3
Fig. 3
ROC curve analysis using miR-9, miR-192 and miR-205 to distinguish the different groups in the serum samples. The area under the curve (AUC) values in the cervical cancer and normal groups (a), the AUC values in the precancer and normal groups (b) and The AUC values in the cervical cancer and precancer groups (c). The red, blue and green lines represent miR-192, miR-9 and miR-205, respectively
See this image and copyright information in PMC

References

    1. Duenas-Gonzalez A, Serrano-Olvera A, Cetina L, Coronel J. New molecular targets against cervical cancer. Int J Women’s Health. 2014;6:1023–1031. doi: 10.2147/IJWH.S49471. - DOI - PMC - PubMed
    1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008-2030): a population-based study. Lancet Oncol. 2012;13:790–801. doi: 10.1016/S1470-2045(12)70211-5. - DOI - PubMed
    1. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550–560. doi: 10.1038/nrc2886. - DOI - PubMed
    1. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–F70. doi: 10.1016/j.vaccine.2012.06.083. - DOI - PubMed
    1. zur Hausen Harald. Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews Cancer. 2002;2(5):342–350. doi: 10.1038/nrc798. - DOI - PubMed

Publication types